Imaging Study Using 99mTc-MY6349 SPECTCT to Detect Trop2 in Female Patients with Triple-negative Breast Cancer Aged 18 to 80

What this Trial Is About

Researchers are evaluating a new imaging agent called 99mTc-MY6349 to detect the presence of Trop2, a protein highly expressed in many cancers including triple-negative breast cancer. This study aims to monitor Trop2 expression in tumors using SPECTCT scans, helping to understand tumor characteristics and guide treatment decisions for patients considering the anti-Trop2 antibody gosatuzumab. Trop2 expression is linked to tumor growth, spread, and patient outcomes. Participants in this study will receive an injection of 99mTc-MY6349 followed by a SPECTCT scan to observe how well the tracer binds to Trop2 in the tumors. This imaging will be compared to 18F-FDG PETCT scans to analyze tumor locations and spread. The study focuses on triple-negative breast cancer patients and looks at the variation of Trop2 expression within primary and metastatic tumors to help inform potential treatment with gosatuzumab. During the study, participants will undergo imaging scans and evaluations of Trop2 levels in their tumors. Researchers will perform semi-quantitative analysis of the imaging results over about one year. The study monitors the ability of the new imaging method to predict response to targeted treatment and assesses tumor heterogeneity. Participants are expected to be followed until study completion with safety considerations for radiation exposure.

99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer